The United Kingdom and the United States have secured a major commercial pact that will maintain zero tariffs on British drug products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to raise expenditure on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these vital products will stay at zero for a timeframe of 36 months.
This development is in response to previous threats to hike duties on patented drug imports, with potential rates discussed as high as 100%.
"This arrangement with the United Kingdom reinforces the worldwide climate for innovative medicines and establishes long-overdue equity to U.S.–U.K. medicine commerce," an announcement said.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the US, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to last September, the UK sold drugs worth £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This deal protects employment, increases investment and facilitates the UK to emerge as a global hub for life sciences," a government official remarked.
Specific NHS Changes
The agreement includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be capped at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The deal comes amid a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were intensified by assertions that American patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the past decade.
